Adage Capital Partners Gp, L.L.C. 89bio, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.6 Billion
- Q3 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in 89bio, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 875,000 shares of ETNB stock, worth $6.95 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
875,000
Previous 400,000
118.75%
Holding current value
$6.95 Million
Previous $3.2 Million
102.09%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding ETNB
# of Institutions
158Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$120 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$113 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$63.5 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$58.6 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$55.7 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $369M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...